November 07, 2016 / 13:52 IST
STR’s Q2 results were broadly in line with our estimates. The company’s H2FY17 EBITDA guidance of Rs 4.4 bn-4.75 bn implies a much better second- half (5-6 US launches including gLovaza + Sevelamer supplies), and is in sync with our FY17 estimate of Rs 7.2 bn. Importantly, emerging markets and the institutional business, which weighed on Q1 margins, revived during Q2. While this is encouraging, rich valuations lead us to restate HOLD on the stock. Our Sep’17 TP stands at Rs 1,190 (Mar’17 TP: Rs 1,130).
For all recommendations, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!